KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Current Taxes (2020 - 2022)

Historic Current Taxes for AbCellera Biologics (ABCL) over the last 3 years, with Q3 2022 value amounting to $23.0 million.

  • AbCellera Biologics' Current Taxes rose 24928.68% to $23.0 million in Q3 2022 from the same period last year, while for Sep 2022 it was $23.0 million, marking a year-over-year increase of 24928.68%. This contributed to the annual value of $35.7 million for FY2021, which is 129.73% down from last year.
  • AbCellera Biologics' Current Taxes amounted to $23.0 million in Q3 2022, which was up 24928.68% from $107.3 million recorded in Q2 2022.
  • AbCellera Biologics' 5-year Current Taxes high stood at $107.3 million for Q2 2022, and its period low was $5.8 million during Q2 2021.
  • For the 3-year period, AbCellera Biologics' Current Taxes averaged around $43.8 million, with its median value being $32.9 million (2021).
  • As far as peak fluctuations go, AbCellera Biologics' Current Taxes tumbled by 129.73% in 2021, and later soared by 174338.72% in 2022.
  • Over the past 3 years, AbCellera Biologics' Current Taxes (Quarter) stood at $36.2 million in 2020, then decreased by 1.3% to $35.7 million in 2021, then crashed by 35.49% to $23.0 million in 2022.
  • Its Current Taxes stands at $23.0 million for Q3 2022, versus $107.3 million for Q2 2022 and $105.6 million for Q1 2022.